Short answer: On Oct. 30, HHS published a draft policy that lets 503A pharmacies compound six peptides, including BPC-157, for individual patients with a prescription while FDA rulemaking is pending. It approves no peptide and does nothing to make these six lawful in dietary supplements. Our read: treat the news as a demand signal, not permission, and document the status of every peptide ingredient you sell.
What it means in plain words
Peptides are short chains of amino acids. The word now covers everything from collagen powder in a coffee aisle to injectable compounds sold online as “research chemicals.” On Oct. 28, the U.S. Department of Health and Human Services announced a draft policy about six of the second kind, and it was published in the Federal Register on Oct. 30.
In plain words: while FDA works on a formal rule, HHS says it will not take action against state-licensed pharmacies and physicians that compound these six peptides for individual patients with a prescription, as long as they follow a list of conditions. The six are BPC-157, TB-500, epitalon, KPV, MOTS-c, and semax.
That is a pharmacy policy. It is not an approval, and it is not a supplement policy. If your team or your investors read the headlines as “peptides are legal now,” this is the conversation to have before anyone touches a formula or a label.
What the policy says
The details below come from the law firm summaries listed under Sources, which quote the notice directly.
- Who it covers. Compounding under section 503A of the Food, Drug, and Cosmetic Act: state-licensed pharmacies, federal facilities, and licensed physicians. It does not cover larger 503B outsourcing facilities, according to Arnold & Porter (Nov. 2).
- The conditions. A valid, patient-specific prescription; one peptide per product (a BPC-157 and TB-500 blend is not covered); ingredients from an FDA-registered manufacturer with a certificate of analysis; set routes of use for each peptide; documented bioavailability for oral forms; adverse event reporting; and a label that reads “This is a compounded drug product. Not for resale.”
- What it is not. Arnold & Porter notes the policy “does not approve any peptide” and does not add any peptide to the official list of substances pharmacies may compound. Frier Levitt (Oct. 28) points out it is not binding on HHS or the public and that HHS can revisit it. Frier Levitt estimates the formal rulemaking could take 12 to 24 months.
- Why HHS did it. The stated aim is to discourage widespread use of research-use-only peptides from foreign manufacturers, as Morgan Lewis (Nov. 10) quotes the notice.
- It is contested. FDA’s drug center had recommended against listing these peptides, while FDA’s outside compounding advisory committee voted in favor in July, per Arnold & Porter. A patient safety group filed a citizen petition on Oct. 23 asking FDA not to allow the compounding.
- Timing. Comments on the draft are due Nov. 13.
The honest question: can I put a peptide in my supplement now?
Not because of this policy. The notice is about compounded drugs. Nothing in it makes any of the six a lawful dietary ingredient.
A supplement ingredient still needs a lawful path. Broadly, that means it was sold as a dietary ingredient before Oct. 15, 1994, or the brand has filed a new dietary ingredient (NDI) notification that FDA has not objected to, or another recognized route applies. Frier Levitt (Oct. 29) lays out a second hurdle: the drug exclusion. An ingredient that was studied as a drug in substantial public clinical investigations before it was sold as a supplement can be kept out of supplements. The firm notes FDA has used that clause before on ingredients such as NAC and NMN.
Attorney Ashish Talati put it plainly to SupplySide Supplement Journal (Nov. 5): enforcement discretion “does not mean the listed peptides are allowed in dietary supplements.” He also said FDA has accepted some peptide ingredients through NDI notifications and rejected others, so the answer depends on the specific ingredient and how it is made.
The trade groups see the same line. Nutritional Outlook (Nov. 2) reports that CRN has called gray-market peptide drugs distinct from lawful dietary supplements, and that NPA worries a compounding listing could be read as making a peptide a drug, which would limit its future use in foods and supplements.
And “research use only” is not a shield. Talati told SupplySide that an RUO or “not for human consumption” label does not stop FDA, which looks at the totality of the marketing and the intended use. Frier Levitt cites a federal prosecution in which investigators called RUO disclaimers “a ruse to avoid FDA scrutiny.” Morgan Lewis reports FDA sent more than 100 enforcement letters in 2026 to companies advertising compounded drugs, and that state attorneys general are signaling more attention to peptide marketing.
Our read
What is real: consumer interest. When a federal agency writes a policy around BPC-157, shoppers notice, and some will come looking for “peptides” in your aisle. That demand is a fair signal for brands that already sell ingredients with an established, documented supplement or food history.
What is overhyped: the idea that this opens a supplement market for the six named peptides. One trade headline called the policy a sign of a coming “boom for supplements.” The boom, if it comes, is in attention, not in legal access. The policy runs through pharmacies and prescriptions, with a label that says “not for resale.”
What we would watch: the final rule, FDA’s response to the citizen petition, and any NDI decisions on peptide ingredients. Each of those can change the picture. A draft enforcement policy cannot.
The brands most at risk are not the ones that ignore this news. They are the ones that let an affiliate, a marketplace seller, or an influencer tie their name to a compound they cannot lawfully sell.
What an established brand should do this quarter
- Inventory every use of the word “peptide.” Labels, product pages, Amazon listings, ads, and influencer briefs. Know where it appears and which ingredient it refers to.
- Document each peptide ingredient’s status. For every one you sell, file the evidence: pre-1994 marketing history, an NDI notification FDA did not object to, or another recognized route. If the file is empty, that is a conversation with counsel this month.
- Cut any research-use-only adjacency. No bundles, affiliate links, or creator content that pairs your products with BPC-157, TB-500, or other compounds named in the policy.
- Audit your claims. Healing, injury recovery, and disease language belong to drugs. Keep supplement claims to supported structure and function statements. The same rule holds across categories: one word can change how a regulator classifies a product, as we showed for cleaners in One Word on Your Label Can Make Your Cleaner an EPA Pesticide.
- Prepare your answer for buyers. Retail and marketplace teams will ask whether your peptide products are affected. A one-paragraph answer backed by your ingredient file is better than a scramble.
- Decide whether to comment. The comment window closes Nov. 13. If your business depends on how peptides are classified, work with your trade association or counsel on whether to weigh in.
Next step
Regulatory news moves supplement shelves faster than most trends. We covered another recent shift in GLP-1 Drugs and the Supplement Category. At Vantage Business Consulting, we help supplement brands decide what to launch, how to position it, and how to talk to retail buyers about it, and we bring in regulatory counsel where a question needs one. If you are planning a launch or relaunch, start with the free Launch Scorecard below.
This is business analysis, not legal advice. Talk to regulatory counsel before you change a formula or a claim. Sources and dates are listed below. We could not open the Federal Register notice directly, so the policy details are taken from the law firm summaries, which quote it.
Sources
- Federal Register, “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,” HHS, Oct. 30, 2026. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
- Arnold & Porter, “HHS Announces Draft Enforcement Discretion Policy Paving Way for Pharmacies to Compound Certain Peptides While FDA Rulemaking Is Pending,” Nov. 2, 2026. https://www.arnoldporter.com/en/perspectives/advisories/2026/11/hhs-announces-draft-enforcement-discretion-policy-paving-way-for-pharmacies
- Frier Levitt, “HHS Announces Landmark Peptide Enforcement Discretion Policy: What Compounding Pharmacies and Peptide Suppliers Need to Know,” Oct. 28, 2026. https://www.frierlevitt.com/articles/hhs-peptide-compounding-enforcement-discretion-policy/
- Frier Levitt, “When a ‘Dietary Supplement’ Label Hides an Unapproved Drug: The Legal Risks of Mislabeled Peptide Products,” Oct. 29, 2026. https://www.frierlevitt.com/articles/mislabeled-peptide-products-fda-enforcement-risks/
- Nutritional Outlook, “What the Interim Compounding Pathway for Peptides Could Mean for Supplement Brands,” Alicia Bigica, Nov. 2, 2026. https://www.nutritionaloutlook.com/view/hhs-peptide-compounding-policy-supplement-industry-implications
- SupplySide Supplement Journal, “Peptide enforcement discretion foretells boom for supplements,” Devon Gholam, Nov. 5, 2026. https://www.supplysidesj.com/supplement-regulations/peptide-enforcement-discretion-foretells-boom-for-dietary-supplements
- Morgan Lewis, “HHS Opens the Door to Compounding Certain Unapproved Peptides,” Nov. 10, 2026. https://www.morganlewis.com/pubs/2026/11/hhs-opens-the-door-to-compounding-certain-unapproved-peptides